- Telesis Bio Reports First Quarter 2024 Financial Results
- Telesis Bio Announces Reverse Stock Split
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
- Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
- Telesis Bio Reports Third Quarter 2023 Financial Results
- Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
- Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
- Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
- Telesis Bio Appoints William J. Kullback Chief Financial Officer
More ▼
Key statistics
As of last trade Telesis Bio Inc (TBIO:NSQ) traded at 3.62, 8.65% above its 52-week low of 3.33, set on May 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.64 |
---|---|
High | 3.64 |
Low | 3.41 |
Bid | 3.50 |
Offer | 3.63 |
Previous close | 3.80 |
Average volume | 24.31k |
---|---|
Shares outstanding | 1.67m |
Free float | 1.04m |
P/E (TTM) | -- |
Market cap | 6.82m USD |
EPS (TTM) | -28.31 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 15:31 BST.
More ▼